Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Science advances - 1 Aug 2017

Deshpande Devyani, Srivastava Shashikant, Chapagain Moti, Magombedze Gesham, Martin Katherine R, Cirrincione Kayle N, Lee Pooi S, Koeuth Thearith, Dheda Keertan, Gumbo Tawanda

Abstract excerpt

There are currently many patients with multidrug-resistant and extensively drug-resistant tuberculosis. Ongoing transmission of the highly drug-resistant strains and high mortality despite treatment remain problematic. The current strategy of drug discovery and development takes up to a decade to bring a new drug to clinical use. We embarked on a strategy to screen all antibiotics in current use and examined them...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Azabicyclo Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ceftazidime

Share to Drug Combinations

Share to Extensively Drug-Resistant Tuberculosis

Share to Genome, Bacterial

Share to Mycobacterium tuberculosis

Share to Tuberculosis, Multidrug-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 28875168
DOI: 10.1126/sciadv.1701102
PMCID: PMC5576880

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.PMID 28875168Read ↗

Antibiotics and resistance: the two-sided coin of the mycobacterial cell wallSemantic proximity Read ↗

Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and TreatmentSemantic proximity Read ↗

Molecular Mechanisms Underlying Antimicrobial Resistance in Mycobacteria.Semantic proximity Read ↗

Lesion penetration predicts tuberculosis regimen success: a validated translational tool for de-risking late-stage drug developmentSemantic proximity Read ↗

Target Identification in Anti-Tuberculosis Drug DiscoverySemantic proximity Read ↗

Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and ModelsSemantic proximity Read ↗

Profiling cell envelope-antibiotic interactions reveals vulnerabilities to β-lactams in a multidrug-resistant bacteriumSemantic proximity Read ↗

Targeting Phenotypically Tolerant Mycobacterium tuberculosisSemantic proximity Read ↗

Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infectionsSemantic proximity Read ↗

The past, present and future of tuberculosis treatment.Semantic proximity Read ↗

Profiling cell envelope-antibiotic interactions reveals vulnerabilities to β-lactams in a multidrug-resistant bacteriumSemantic proximity Read ↗

Mycobacterium abscessus: a new antibiotic nightmareSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.